Flamel Technologies Announces New Composition of Its Scientific Adviso

    Pharmaceutical Writers/Business Editors

    LYON, France--(BUSINESS WIRE)--Jan. 26, 2005--Flamel Technologies S.A. ("Flamel") (Nasdaq:FLML) announced today changes in the composition of its scientific advisory board. The new board will consist of Dr. Jean-Marie Lehn (Nobel Laureate in Chemistry, 1987) and Pierre-Gilles de Gennes (Nobel Laureate in Physics, 1991) as well as Professor Christian Trepo.
    Dr. Trepo replaces Sir John Vane, who, with Dr. Lehn and Dr. de Gennes, had served on Flamel's scientific advisory board. Sir John died in November, 2004.
    Gerard Soula, PhD., founder, president and chief executive officer of Flamel, said, "We are very pleased to include Dr. Trepo on our scientific advisory board. I am convinced that Dr. Trepo, a world-recognized expert in liver disease, particularly hepatitis B and C, will help Flamel to develop additional Medusa projects. Furthermore, his expertise complements the backgrounds of Dr. Lehn and Dr. de Gennes."
    Dr Soula continued: "We regret the passing of Sir John Vane, who was a member of our scientific advisory board until his death in November. We greatly appreciate his contributions to Flamel and to science generally and are saddened by his passing."

    Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump(R) is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa(R) technology is designed to deliver controlled-release formulations of therapeutic proteins.

    This document contains a number of matters, particularly as related to financial projections and the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
    The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
    These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances.
    These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2003.

--30--JO/ph*

CONTACT: Flamel Technologies S.A. Gerard Soula, (33) 4-72-78-34-34 Fax: (33) 4-72-78-34-35 Soula@flamel.com or Stephen H. Willard, 202-862-3993 Fax: 202-862-3933 Willard@flamel.com or Charles Marlio, 202-862-8535 Fax: 202-862-3933 Marlio@flamel.com

KEYWORD: FRANCE INTERNATIONAL EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Flamel Technologies S.A.

Copyright Business Wire 2005